Researchers from SRM Institute of Science and Technology, led by Dr. KN Aruljothi, have published a study in ExRNA ...

NiKang Therapeutics has concluded the first cohort dosing in the open-label Phase I trial of NKT3964 as a monotherapy for ...

Cyclin-dependent kinases (CDKs) are protein kinases involved in critical cellular processes, such as cell cycle or transcription, whose activity requires association with specific cyclin subunits.

1 provide one explanation. The KSHV cyclin directs cellular cyclin-dependent kinase 6 (CDK6) to phosphorylate cellular Bcl-2, an inhibitor of apoptosis. Phosphorylation renders Bcl-2 unstable ...

Get Instant Summarized Text (Gist) Cyclin-dependent kinase 2 (CDK2) is identified as a potential target for cancer therapy, particularly in overcoming resistance to CDK4/6 inhibitors used in ...

The results showed statistically significant and clinically meaningful improvement in progression-free survival compared with the standard-of-care treatment, the company said.

Cyclacel Pharmaceuticals (NASDAQ:CYCC – Get Free Report) is expected to post its quarterly earnings results before the market opens on Tuesday, March 18th. Analysts expect Cyclacel Pharmaceuticals to ...

Vepdegestrant is a novel proteolysis targeting chimera protein degrader designed to target and degrade the estrogen receptor.

Arvinas and Pfizer's Phase 3 trial shows vepdegestrant significantly improves progression-free survival in breast cancer patients.

Verzenio plus Faslodex improved progression-free survival in HR+/HER2– advanced breast cancer after CDK/6i failure, with a ...

Arvinas & Pfizer announce positive topline results from phase 3 VERITAC-2 clinical trial: New Haven, Connecticut Wednesday, March 12, 2025, 10:00 Hrs [IST] Arvinas, Inc., a clinic ...

The exact molecular functions of Polo-like kinase 1 (PLK1) in mitotic prophase are not fully understood. This study shows ...